Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Q2 2011 by GlobalMarketsDirect

VIEWS: 4 PAGES: 47

More Info
									Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, Q2 2011




Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline
                  Review, Q2 2011
                                                                                     Reference Code: GMDHC1006IDB

                                                                                     Publication Date: April 2011




Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, Q2 2011                                            GMDHC1006IDB / Pub April 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                   Page(1)
Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, Q2 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                                             2
List of Tables                                                                                                                                4
List of Figures                                                                                                                               5
Introduction                                                                                                                                  6
    Global Markets Direct Report Coverage                                                                                                     6
Systemic Juvenile Idiopathic Arthritis (SJIA) Overview                                                                                        7
Therapeutics Development                                                                                                                      8
    An Overview of Pipeline Products for Systemic Juvenile Idiopathic Arthritis (SJIA)                                                        8
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Development by Companies                                                    10
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Investigation by Universities/Institutes                                    11
Late Stage Products                                                                                                                          12
    Comparative Analysis                                                                                                                     12
Mid Clinical Stage Products                                                                                                                  13
    Comparative Analysis                                                                                                                     13
Early Clinical Stage Products                                                                                                                14
    Comparative Analysis                                                                                                                     14
Pre-Clinical Stage Products                                                                                                                  15
    Comparative Analysis                                                                                                                     15
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Products under Development by Companies                                         16
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Products under Investigation by Universities/Institutes                         17
Companies Involved in Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Development                                                 18
    F. Hoffmann-La Roche Ltd.                                                                                                                18
    Novartis AG                                                                                                                              18
    Protalix BioTherapeutics, Inc.                                                                                                           19
    XOMA Ltd.                                                                                                                                19
    Italfarmaco S.p.A.                                                                                                                       20
Systemic Juvenile Idiopathic Arthritis (SJIA) - Therapeutics Assessment                                                                      21
    Assessment by Monotherapy Products                                                                                                       21
    Assessment by Combination Products                                                                                                       22
    Assessment by Route of Administration                                                                                                    23
    Assessment by Molecule Type                                                                                                              25
Drug Profiles                                                                                                                                27
    ACZ885 - Drug Profile                                                                                                                    27
         Product Description                                                                                                                 27
         Mechanism of Action                                                                                                                 27
         R&D Progress                                                                                                                        27
    Actemra - Drug Profile                                                                                                                   29
         Product Description                                                                                                                 29
         Mechanism of Action                                                                                                                 29
         R&D Progress                                                                                                                        29
         Product Description                                                                                                                 31
         Mechanism of Action                                                                                                                 31
         R&D Progress                                                                                                                        31
    XOMA 052 - Drug Profile                                                                                                                  32
         Product Description                                                                                                                 32
         Mechanism of Action                                                                                                                 32
         R&D Progress                                                                                                                        32


Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, Q2 2011                                               GMDHC1006IDB / Pub April 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                     Page(2)
Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, Q2 2011


    Anakinra - Drug Profile                                                                                                              34
         Product Description                                                                                                             34
         Mechanism of Action                                                                                                             34
         R&D Progress                                                                                                                    34
    Infliximab + Methotrexate - Drug Profile                                                                                             35
         Product Description                                                                                                             35
         Mechanism of Action                                                                                                             35
         R&D Progress                                                                                                                    35
    Rilonacept - Drug Profile                                                                                                            36
         Product Description                                                                                                             36
         Mechanism of Action                                                                                                             36
         R&D Progress                                                                                                                    36
    Givinostat - Drug Profile                                                                                                            37
         Product Description                                                                                                             37
         Mechanism of Action                                                                                                             37
         R&D Progress                                                                                                                    38
    Methotrexate - Drug Profile                                                                                                          39
         Product Description                                                                                                             39
         Mechanism of Action                                                                                                             39
         R&D Progress                                                                                                                    39
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Drug Profile Updates                                                        40
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Discontinued Products                                                       42
    Systemic Juvenile Idiopathic Arthritis (SJIA) - Featured News                                                                        43
         Oct 18, 2010: Roche Submits ACTEMRA/RoACTEMRA Supplemental Marketing Authorizations In US And Europe For Treatment Of
         Systemic Juvenile Idiopathic Arthritis                                                                                          43
         Jun 15, 2010: TxCell Successfully Completes Preclinical Development of TX-RAD in Inflammatory Arthritis                         43
         Nov 20, 2009: Roche Announces Phase III Clinical Study Results Of ACTEMRA In Children With Systemic Onset Juvenile Idiopathic
         Arthritis (sJIA)                                                                                                                44
Appendix                                                                                                                                 46
    Methodology                                                                                                                          46
         Coverage                                                                                                                        46
         Secondary Research                                                                                                              46
         Primary Research                                                                                                                46
         Expert Panel Validation                                                                                                         47
    Contact Us                                                                                                                           47
    Disclaimer                                                                                                                           47




Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, Q2 2011                                           GMDHC1006IDB / Pub April 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(3)
Systemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, Q2 2011




Lis t o f Ta b le s
Number of Products Under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), Q2 2011                                       8

Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) – Comparative Analysis, Q2 2011                          9

Comparative Analysis by Late Stage Development, Q2 2011                                                                              12

Comparative Analysis by Mid Clinical Stage Development, Q2 2011                                                                      13

Comparative Analysis by Early Clinical Stage Development, Q2 2011                                                                    14

Comparative Analysis by Pre-Clinical Stage Development, Q2 2011                                                                      15

F. Hoffmann-La Roche Ltd., 2011                                                                                                      18

Novartis AG, 2011                                                                                                                    18

Protalix BioTherapeutics, Inc., 2011                                                                                                 19

XOMA Ltd., 2011                                                                                                                      19

Italfarmaco S.p.A., 2011                                                                                                             20

Assessment by Monotherapy Products, Q2 2011                                               
								
To top